Business Wire

Adtran sets new industry benchmarks with optical pumping cesium atomic clocks

Share

Adtran today launched two new optical cesium atomic clocks that set new standards in network time synchronization: the OSA 3300 Super High-Performance (OSA 3300 SHP) and the OSA 3350 Super Enhanced Primary Reference Clock+ (OSA 3350 SePRC+). As part of Adtran’s Oscilloquartz portfolio of industry-first optical cesium clocks, the devices leverage unique, state-of-the-art optical pumping technology to meet evolving demands across applications from scientific research to critical PNT infrastructure. The OSA 3300 SHP offers exceptional stability and accuracy, making it a valuable tool for metrology institutes and scientific research facilities. In contrast, the OSA 3350 SePRC+ is specifically designed to enhance holdover capabilities for PNT services. It maintains 100 days of 100-nanosecond precision, providing continuous and accurate timing even in environments where GPS/GNSS is unavailable. This makes it a crucial component for ensuring the integrity of mission-critical networks and supporting vital infrastructure and defense operations with reliable backup timing.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240613778509/en/

Adtran’s new optical pumping cesium clocks are a significant breakthrough for the networking industry. (Photo: Business Wire)

“Our two new optical cesium clocks represent a major breakthrough, offering substantial benefits to a wide variety of industries. Take the OSA 3350 SePRC+, for instance – it ensures 100-nanosecond accuracy over a span of more than three months. This level of precision and stability is critical for infrastructures relying on continuous PNT services, providing our customers with supreme reliability and robust protection against escalating cyber threats to GPS/GNSS,” said Gil Biran, GM of Oscilloquartz, Adtran. “In an era marked by rising global tensions and heightened risks of state-sponsored interference in satellite communications, our latest innovation has arrived at a pivotal moment. It will greatly enhance our capacity to address the demand for secure and reliable network timing around the world. Building on our 75-year legacy and unmatched expertise, the OSA 3350 SePRC+ exemplifies our commitment to excellence in assured PNT technology. As pioneers in the field, we continue to set new benchmarks, consistently improving standards to meet the dynamic needs of our customers and the broader market.”

The OSA 3300 SHP and OSA 3350 SePRC+ redefine the capabilities of PRCs and ePRCs, unlocking new possibilities in their respective domains. The OSA 3300 SHP, with its superior Allan Deviation (ADEV) performance – twice as accurate as the 3300 HP with the same 10-year lifespan – ensures exceptional stability and accuracy, making it an ideal choice for metrology institutes and scientific research facilities. Its advanced feature set enables these institutions to achieve new levels of precision in their timekeeping and calibration processes, directly driving advancements in scientific research and industrial applications. Meanwhile, the OSA 3350 SePRC+ is specifically designed to enhance holdover capabilities for PNT services. This high-end optical cesium clock, together with our Super ePRTC+ combiner can maintain 100 days of 100-nanosecond precision, far exceeding previous industry records, and ensuring continuous and accurate timing even in environments where GPS/GNSS are unavailable.

“Our OSA 3300 SHP provides unprecedented accuracy in timekeeping, maintaining nanosecond precision over extended periods. This level of enhanced accuracy and stability is crucial for scientific research and metrology, supporting high-precision experiments and the calibration of instruments to the highest standards. The 3300 SHP allows researchers to conduct groundbreaking experiments in fields like quantum mechanics and relativity, where extreme accuracy is paramount,” commented Patrick Berthoud, time and frequency chief scientist at Oscilloquartz, Adtran. “At Oscilloquartz, we’re dedicated to advancing time and frequency technology, leveraging our world-renowned Swiss expertise in this field. Our latest innovations demonstrate our commitment to delivering superior solutions that meet the evolving demands of our customers, driving progress in both scientific research and industrial applications.”

About Adtran

ADTRAN Holdings, Inc. (NASDAQ: ADTN and FSE: QH9) is the parent company of Adtran, Inc., a leading global provider of open, disaggregated networking and communications solutions that enable voice, data, video and internet communications across any network infrastructure. From the cloud edge to the subscriber edge, Adtran empowers communications service providers around the world to manage and scale services that connect people, places and things. Adtran solutions are used by service providers, private enterprises, government organizations and millions of individual users worldwide. ADTRAN Holdings, Inc. is also the largest shareholder of Adtran Networks SE, formerly ADVA Optical Networking SE. Find more at Adtran, LinkedIn and X.

Published by

ADTRAN Holdings, Inc.

www.adtran.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20240613778509/en/

Contacts

For media
Gareth Spence
+44 1904 699 358
public.relations@adtran.com

For investors
Steven Williams
+49 89 890 665 918
investor@adtran.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Seoul Semiconductor: Philips Lighting Products Ordered to Recall 7-Year-Old Items26.12.2024 08:00:00 CET | Press Release

The German District Court of Düsseldorf, on November 19 ruled in favor of Seoul Semiconductor (KOSDAQ:046890) in the patent infringement lawsuits, and also ordered that products manufactured by Philips Lighting and sold since March 2017 be recalled and destroyed. The Court also ruled that a fine of up to €250,000 would be imposed for each violation of this order. On December 17, the German Federal Patent Court also affirmed the validity of these patents, which solidifies the strength of many related patents. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241225151382/en/ Application Examples with CRI 70 or Higher (Photo: Seoul Semiconductor) These court orders relate to the core technology used to achieve CRI 70 (Color Rendering Index 70%) or higher, applicable to all home lighting, automotive lighting products, IT flash, and backlights. Since the effects of these judgments are applicable to all products infringing on the pa

ispace-EUROPE and the Italian Space Agency (ASI) Sign Payload Services Agreement to Transport a Laser Retroreflector Array (LaRA2) on the Moon Surface26.12.2024 08:00:00 CET | Press Release

ispace EUROPE S.A. (ispace-EUROPE), the Luxembourg-based subsidiary of ispace, inc., and the Italian Space Agency (ASI) have signed a payload services agreement to transport a Laser Retroreflector Array (LaRA2) to enable accurate position measurements on the Moon via laser ranging experiments, the two organizations announced today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241225137548/en/ The shape of LaRA2, a palm-sized dome (Photo: Business Wire) The agreement marks the first full-scale contract between ispace-EUROPE and ASI, with both organizations looking to joint future lunar development. LaRA2 is a small, robust, and lightweight instrument built to work without any power source and to survive the harsh surface conditions on the Moon for an extended period of time. It features a precise array of retroreflectors (corner cube prisms) designed to reflect laser beams directly back to their source, regardless of the an

Datopotamab Deruxtecan Application in the EU for Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer Voluntarily Withdrawn24.12.2024 08:00:00 CET | Press Release

Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/Nasdaq: AZN) have voluntarily withdrawn the marketing authorization application (MAA) in the EU for datopotamab deruxtecan (Dato-DXd) for the treatment of adult patients with locally advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) based on the TROPION-Lung01 phase 3 trial. The decision to withdraw the MAA was informed by feedback from the Committee for Medicinal Products for Human Use of the European Medicines Agency (EMA). Daiichi Sankyo and AstraZeneca will continue to work to bring datopotamab deruxtecan to patients with lung cancer in the EU who can benefit and are committed to unlocking the potential of this medicine in lung cancer through our robust clinical development program which includes seven pivotal trials in various lung cancer settings. Datopotamab deruxtecan is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being jointly developed by Dai

Vertex to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 1323.12.2024 22:05:00 CET | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Dr. Reshma Kewalramani, Chief Executive Officer and President, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 10:30 a.m. ET/7:30 a.m. PT. A live webcast of management's remarks will be available through the Vertex website, www.vrtx.com in the "Investors" section under the "News and Events" page. A replay of the conference webcast will be archived on the company's website. About Vertex Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has approved medicines that treat the underlying causes of multiple chronic, life-shortening genetic diseases — cystic fibrosis, sickle cell disease and transfusion-dependent beta thalassemia — and continues to advance clinical and research programs in these diseases. Vertex also has a robust clinical pipeline of investigational

Perma-Pipe International Holdings, Inc. Announces Third Quarter Financial Results23.12.2024 18:43:00 CET | Press Release

Perma-Pipe International Holdings, Inc. (NASDAQ: PPIH) announced today financial results for the second quarter and fiscal year-to-date period ended October 31, 2024. "Net sales for the third quarter were $41.6 million, a decrease of $4.1 million, as compared to the same quarter last year. Net income attributable to common stock of $2.5 million was an increase of $0.5 million, or 29%, compared to $1.9 million in the third quarter of 2023. For the nine months ended October 31, 2024, net sales of $113.4 million represent an increase of 3% compared to the nine months ended October 31, 2023. The net income attributable to common stock of $7.2 million was an increase of $5.4 million, or 294%, compared to net income attributable to common stock of $1.8 million in the nine months ended October 31, 2023,” noted President and CEO David Mansfield. “Backlog in the third quarter shows considerable growth and now stands at $114.2 million. This is the equivalent to approximately nine months revenue

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye